Chokri Jeribi, country chair of Sanofi Tunisia since 2016, is responsible for the development and market leadership hold of Sanofi’s affiliate in Tunisia. In this interview he stresses the importance that clinical trials activities for both the company and the country. Additionally, Jeribi documents the unique collaboration system with local laboratories and the technological transfers that result from it. He further explains the combination of the cooperation model and continuous investment strategy in production capabilities has led Sanofi to produce 80 percent of its products sold on the territory in Tunisia.
You have worked for Sanofi for 27 years and were appointed director of the subsidiary of Sanofi Tunisia in 2016. How have you adapted to these new functions and what actions did you first take?
"Tunisia should make the development of clinical trials a priority because they are the fastest way of giving patients access to the latest treatments and these activities create economic wealth."
